Dulaglutide as a demethylating agent to improve the outcome of breast cancer.
Epigenomics
; 15(24): 1309-1322, 2023 Dec.
Article
em En
| MEDLINE
| ID: mdl-38174426
ABSTRACT
Background:
Dulaglutide emerged as a promising therapeutic option for diabetes mellitus Type 2 (DM2).Aims:
Owing to epigenetic similarities between the pathophysiology of DM2 and breast cancer (BC), we investigated the antitumor effect of dulaglutide. Materials &methods:
To investigate the effect of dulaglutide, we analyzed the expression of methylated gene promoter regions in BC (ESR1, CDH1 and ADAM33).Results:
Dulaglutide increased the expression of ESR1, CDH1 and ADAM33 up to fourfold in the MDA-MB-231 lineage by demethylating the gene promoter regions. This effect was translated to in vivo antitumoral activity and revealed significant tumor inhibition by combining the half-dose of methotrexate with dulaglutide.Conclusion:
This therapy may mitigate the severe side effects commonly associated with chemotherapy.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Mama
/
Diabetes Mellitus Tipo 2
Limite:
Female
/
Humans
Idioma:
En
Revista:
Epigenomics
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Brasil
País de publicação:
Reino Unido